Huntington's disease: Neural dysfunction linked to inositol polyphosphate multikinase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 31, 2015, Pages 9751-9756

  Ahmed, Ishrat ^a   Sbodio, Juan I ^a   Harraz, Maged M ^a   Tyagi, Richa ^a   Grima, Jonathan C ^a   Albacarys, Lauren K ^a   Hubbi, Maimon E ^a   Xu, Risheng ^a   Kim, Seyun ^b   Paul, Bindu D ^a   Snyder, Solomon H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Akt; Ctip2|; Huntington's disease|; Inositol polyphosphate multikinase|; IPMK; |

Indexed keywords

CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; INOSITOL POLYPHOSPHATE; INOSITOL POLYPHOSPHATE MULTIKINASE; UNCLASSIFIED DRUG; BCL11B PROTEIN, MOUSE; MESSENGER RNA; PHOSPHOTRANSFERASE; PROTEIN KINASE B; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; ADULT; AGED; ANIMAL; BIOCATALYSIS; DEMOGRAPHY; DEPENDOPARVOVIRUS; DISEASE MODEL; ENZYME STABILITY; ENZYMOLOGY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; MITOCHONDRION; MOTOR ACTIVITY; NEOSTRIATUM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; POSTMORTEM CHANGE; SIGNAL TRANSDUCTION; SURVIVAL; TRANSGENIC MOUSE;

ANIMALIA; MURINAE;

ADULT; AGED; ANIMALS; BIOCATALYSIS; DEMOGRAPHY; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENZYME STABILITY; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE, TRANSGENIC; MIDDLE AGED; MITOCHONDRIA; MOTOR ACTIVITY; NEOSTRIATUM; NEURONS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POSTMORTEM CHANGES; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84938839518     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1511810112     Document Type: Article

References (53)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-983.
2. Reiner A, et al. (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 85(15):5733-5737.
3. Beal MF, et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321(6066):168-171.
4. Zuccato C, et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293(5529):493-498.
5. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19(5):233-238.
6. Dunah AW, et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296(5576):2238-2243.
7. Desplats PA, et al. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96(3):743-757.
8. Desplats PA, Lambert JR, Thomas EA (2008) Functional roles for the striatalenriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.Neurobiol Dis 31(3): 298-308.
9. Tang B, et al. (2011) Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling. PLoS One 6(9):e23691.
10. Odom AR, Stahlberg A, Wente SR, York JD (2000) A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science 287(5460):2026-2029.
11. Saiardi A, Erdjument-Bromage H, Snowman AM, Tempst P, Snyder SH (1999) Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Curr Biol 9(22):1323-1326.
12. Chakraborty A, Kim S, Snyder SH (2011) Inositol pyrophosphates as mammalian cell signals. Sci Signal 4(188):re1.
13. Irvine RF, Schell MJ (2001) Back in the water: The return of the inositol phosphates. Nat Rev Mol Cell Biol 2(5):327-338.
14. Maag D, et al. (2011) Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proc Natl Acad Sci USA 108(4):1391-1396.
15. Resnick AC, et al. (2005) Inositol polyphosphate multikinase is a nuclear PI3-kinase with transcriptional regulatory activity. Proc Natl Acad Sci USA 102(36):12783-12788.
16. Kim S, et al. (2011) Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab 13(2):215-221.
17. Xu R, et al. (2013) Inositol polyphosphate multikinase is a transcriptional coactivator required for immediate early gene induction. Proc Natl Acad Sci USA 110(40): 16181-16186.
18. Xu R, et al. (2013) Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death. Sci Signal 6(269):ra22.
19. Kim E, et al. (2013) Inositol polyphosphate multikinase is a coactivator for serum response factor-dependent induction of immediate early genes. Proc Natl Acad Sci USA 110(49):19938-19943.
20. Trettel F, et al. (2000) Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells. Hum Mol Genet 9(19):2799-2809.
21. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493-506.
22. Menalled LB, et al. (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One 7(12): e49838.
23. Gines S, et al. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12(5):497-508.
24. Colin E, et al. (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21(6):1478-1488.
25. Guyenet SJ, et al. (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp 39:1787-1789.
26. Boutell JM, et al. (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 8(9): 1647-1655.
27. Steffan JS, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857):739-743.
28. Steffan JS, et al. (2000) The Huntington's disease protein interacts with p53 and CREBbinding protein and represses transcription. Proc Natl Acad Sci USA 97(12):6763-6768.
29. Arlotta P, Molyneaux BJ, Jabaudon D, Yoshida Y, Macklis JD (2008) Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J Neurosci 28(3):622-632.
30. de la Monte SM, Vonsattel JP, Richardson EP, Jr (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47(5):516-525.
31. Koga H, et al. (2011) Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. J Neurosci 31(50):18492-18505.
32. Pearce LR, Komander D, Alessi DR (2010) The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11(1):9-22.
33. Humbert S, et al. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2(6):831-837.
34. Rangone H, et al. (2005) Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem 280(23):22021-22028.
35. Zala D, et al. (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17(24):3837-3846.
36. Metzler M, et al. (2010) Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci 30(43):14318-14329.
37. Wickramasinghe VO, et al. (2013) Human inositol polyphosphate multikinase regulates transcript-selective nuclear mRNA export to preserve genome integrity. Mol Cell 51(6):737-750.
38. Zuccato C, et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35(1):76-83.
39. Plotkin JL, et al. (2014) Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 83(1):178-188.
40. Wang YB, et al. (2012) Adaptor protein APPL1 couples synaptic NMDA receptor with neuronal prosurvival phosphatidylinositol 3-kinase/Akt pathway. J Neurosci 32(35): 11919-11929.
41. Carter RJ, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19(8):3248-3257.
42. Ross CA, Tabrizi SJ (2011) Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83-98.
43. van der Burg JM, Björkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington's disease.Lancet Neurol 8(8):765-774.
44. Bang S, et al. (2012) AMP-activated protein kinase is physiologically regulated by inositol polyphosphate multikinase. Proc Natl Acad Sci USA 109(2):616-620.
45. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase-development of the energy sensor concept. J Physiol 574(Pt 1):7-15.
46. Ju TC, et al. (2011) Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 194(2):209-227.
47. Subramaniam S, Sixt KM, Barrow R, Snyder SH (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324(5932):1327-1330.
48. Sbodio JI, Paul BD, Machamer CE, Snyder SH (2013) Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease. Cell Reports 4(5):890-897.
49. Tirard M, et al. (2012) In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice. Proc Natl Acad Sci USA 109(51): 21122-21127.
50. Bang S, Steenstra C, Kim SF (2012) Striatum specific protein, Rhes regulates AKT pathway. Neurosci Lett 521(2):142-147.
51. Paul BD, et al. (2014) Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature 509(7498):96-100.
52. 2S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol 13(8):499-507.
53. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.